Immunome Competitors

Immunome (NASDAQ:IMNM) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Earnings and Valuation

This table compares Immunome and Stoke Therapeutics' revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Immunome and Stoke Therapeutics' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Immunome and Stoke Therapeutics, as reported by MarketBeat.

Immunome presently has a consensus price target of $18.00, indicating a potential downside of 35.32%. Stoke Therapeutics has a consensus price target of $64.3333, indicating a potential upside of 87.72%. Given Stoke Therapeutics' higher probable upside, analysts clearly believe Stoke Therapeutics is more favorable than Immunome.

Summary

Immunome beats Stoke Therapeutics on 4 of the 6 factors compared between the two stocks.

Immunome (NASDAQ:IMNM) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.

Insider and Institutional Ownership

52.5% of Ocular Therapeutix shares are held by institutional investors. 7.7% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Immunome and Ocular Therapeutix's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings for Immunome and Ocular Therapeutix, as reported by MarketBeat.

Immunome presently has a consensus price target of $18.00, indicating a potential downside of 35.32%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 50.30%. Given Ocular Therapeutix's higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Immunome.

Earnings and Valuation

This table compares Immunome and Ocular Therapeutix's revenue, earnings per share (EPS) and valuation.

Immunome has higher earnings, but lower revenue than Ocular Therapeutix.

Summary

Ocular Therapeutix beats Immunome on 5 of the 9 factors compared between the two stocks.

Phathom Pharmaceuticals (NASDAQ:PHAT) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Insider and Institutional Ownership

73.8% of Phathom Pharmaceuticals shares are held by institutional investors. 39.8% of Phathom Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Phathom Pharmaceuticals and Immunome's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Phathom Pharmaceuticals and Immunome, as provided by MarketBeat.

Phathom Pharmaceuticals currently has a consensus target price of $53.00, indicating a potential upside of 39.03%. Immunome has a consensus target price of $18.00, indicating a potential downside of 35.32%. Given Phathom Pharmaceuticals' higher probable upside, analysts plainly believe Phathom Pharmaceuticals is more favorable than Immunome.

Valuation & Earnings

This table compares Phathom Pharmaceuticals and Immunome's top-line revenue, earnings per share and valuation.

Repare Therapeutics (NASDAQ:RPTX) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, risk, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Repare Therapeutics and Immunome, as provided by MarketBeat.

Repare Therapeutics currently has a consensus target price of $39.40, indicating a potential upside of 15.07%. Immunome has a consensus target price of $18.00, indicating a potential downside of 35.32%. Given Repare Therapeutics' higher probable upside, analysts plainly believe Repare Therapeutics is more favorable than Immunome.

Valuation & Earnings

This table compares Repare Therapeutics and Immunome's top-line revenue, earnings per share and valuation.

Profitability

This table compares Repare Therapeutics and Immunome's net margins, return on equity and return on assets.

Insider and Institutional Ownership

64.8% of Repare Therapeutics shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Repare Therapeutics beats Immunome on 4 of the 4 factors compared between the two stocks.

Immunome (NASDAQ:IMNM) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Immunome and Innoviva, as provided by MarketBeat.

Immunome currently has a consensus target price of $18.00, indicating a potential downside of 35.32%. Innoviva has a consensus target price of $10.00, indicating a potential downside of 14.89%. Given Innoviva's higher probable upside, analysts plainly believe Innoviva is more favorable than Immunome.

Earnings and Valuation

This table compares Immunome and Innoviva's top-line revenue, earnings per share and valuation.

Innoviva has higher revenue and earnings than Immunome.

Profitability

This table compares Immunome and Innoviva's net margins, return on equity and return on assets.

Insider & Institutional Ownership

71.5% of Innoviva shares are held by institutional investors. 0.3% of Innoviva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Innoviva beats Immunome on 8 of the 10 factors compared between the two stocks.

Immunome (NASDAQ:IMNM) and Praxis Precision Medicines (NASDAQ:PRAX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership.

Analyst Ratings

This is a summary of recent ratings and price targets for Immunome and Praxis Precision Medicines, as provided by MarketBeat.

Immunome currently has a consensus target price of $18.00, indicating a potential downside of 35.32%. Praxis Precision Medicines has a consensus target price of $60.3333, indicating a potential upside of 138.47%. Given Praxis Precision Medicines' higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Immunome.

Earnings and Valuation

This table compares Immunome and Praxis Precision Medicines' top-line revenue, earnings per share and valuation.

Profitability

This table compares Immunome and Praxis Precision Medicines' net margins, return on equity and return on assets.

Summary

Praxis Precision Medicines beats Immunome on 2 of the 2 factors compared between the two stocks.